MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
A phase 2 trial of MEN1703, Glofitamab in hodgkin lymphoma and non-hodgkin lymphoma, run by Ryvu Therapeutics SA, now recruiting.
Overview
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) is a phase 2 interventional study registered as NCT06534437 by Ryvu Therapeutics SA, with 178 participants planned, started 2024-12-05 and due to reach its primary completion in 2026-12. Interventions recorded: MEN1703, Glofitamab. Conditions listed: Non-Hodgkin Lymphoma, B-cell. No results are recorded here; the registry entry is the source.
Setting
An Open Label, Phase 2 Clinical Trial of MEN1703 as Monotherapy and in Combination With Glofitamab in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
Phase
Phase 2
Sponsor
Ryvu Therapeutics SA
Registry
Enrolled
178
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Matu
Shares Glofitamab, Non-Hodgkin lymphoma (all types), Hodgkin lymphoma.
- TrialT-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
- TrialA Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Ly
- TrialA Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Shares Glofitamab, Non-Hodgkin lymphoma (all types), Hodgkin lymphoma.
- TrialA Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treat
- TrialA Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients
- TrialA Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
- TrialEvaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Shares Glofitamab, Hodgkin lymphoma.